New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures PHILADELPHIA, Jan. 6, 2026 /PRNewswire/ -- ...
Dupilumab, a fully human monoclonal antibody, inhibits the signaling of the interleukin 4 (IL-4) and IL-13 pathways.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback